Although most of the early studies supported TLR3 activation exerting neuroprotective effects in the pathogenic courses of MS/EAE, we can see that TLR3 also appears to promote the pathogenesis of MS, which may be related to the activation of different cell types, ligands, different disease stages and different signaling pathways. Here, TLR3 is linked to myeloid sarcoma.